Table 1.
Lipid-lowering effect of rosuvastatin treatment on 64 hyperlipidemia patients.
| Patient group# | Number (male, female) | Age (mean) | Triglycerides (mmole/L) (mean ±SD) | Cholesterol (mmole/L) (mean ±SD) |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total cholesterol |
Low-density lipoprotein |
High density lipoprotein |
||||||||
| Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | |||
| Group I | 33 (23,10) | 64.24 | 3.56 ± 1.93 | 1.29 ± 0.55 | 5.36 ± 1.63 | 3.12 ± 0.51∗ | 1.15 ± 0.27 | 1.16 ± 0.36 | 3.52 ± 1.02 | 1.46 ± 1.27∗ |
| Group II | 31 (22,9) | 65.55 | 3.13 ± 1.57 | 1.50 ± 0.66 | 5.85 ± 1.36 | 4.26 ± 0.86 | 1.19 ± 0.32 | 1.21 ± 0.26 | 3.65 ± 0.93 | 2.50 ± 0.70 |
#All patients were classified into two groups: Group I patients’ blood lipid levels back to the normal after rosuvastatin treatment, Group II patients’ blood lipid levels above the normal after treatment. ∗Significant difference between pre- and post-treatment lipid levels measured with Assay Kits (BioSino Bio-Technology & Science Inc., Beijing, China), P < 0.05.